Synergistic Effect of Sequential Administration of Mitoguazone (MGBG) and Gemcitabine in Treating Tissue Cultured Human Breast Cancer Cells and Mammary Rat Tumors

References

• Ishmael D.R., Nordquist R.E., Bottomley R.H., et al. Vitamin A acid (Retinoic acid) as an adjunct to increase adriamycin cytotoxicity in human breast cancer cells in vitro. Prev. Detection Cancer. 1977; 1: 727–736
   Google Scholar
• Tsubura A., Hioki K., Kiyozuka Y., et al. Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J. Cancer Res. Clin. Oncol. 2000; 126: 448–454
   PubMed Web of Science ®Google Scholar
• Kreis W., Budman D.R., Liu X.M., et al. Synergistic effect of estramustine and (3′-keto-Bmt1)-(Val2)-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells. Biochem. Pharmacol. 1999; 58: 1115–1121
   PubMed Web of Science ®Google Scholar
• Holmes F.A. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Semin. Oncol. 1996; 23((Suppl. 11))46–56
   PubMedGoogle Scholar
• Budman D.R., Calabro A., Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anti-Cancer Drugs 1998; 9: 697–702
   PubMed Web of Science ®Google Scholar
• Thiel J., Dralle F. Zur Kenntnis des amino gunidins. I. Condensations-produkte de amidoguanidins mit aldehyden and ketonen der fettreihe. Ann. Chem. 1898; 302: 275–299
   Google Scholar
• Williams-Ashman H.G., Schenone A. Methylgloxyl-bis(guanylhydrazone) as a potent inhibitor of mammalian and yeast S-adenosylmethionine decarboxylases. Biochem. Biophys. Res. Commun. 1972; 46: 288–295
   PubMed Web of Science ®Google Scholar
• Regelson W., Holland J.F. Initial clinical study of parenteral methylgloxyl-bis-(guanylhydrazone) diacetate. Cancer Chemother. Rep. 1961; 1: 81–86
   Google Scholar
• Rosenblum M.G., Keating M.J., Yap B.S., et al. Pharmacokinetics of [14C] methylgloxyl-bis (guanylhydrazone) in patients with leukemia. Cancer Res. 1981; 41: 1748–1750
   PubMed Web of Science ®Google Scholar
• Hart R.D., Roboz J., Wu K., et al. Clinical and pharmacologic studies with weekly and biweekly methyl-gloxyl bis-guanylhydrazone (methyl-GAG). Proc. Am. Assoc. Cancer Res. 1980; 21: 181
   Web of Science ®Google Scholar
• Knight W.A., II, Livingston R.B., Fabian C., et al. Phase I–II trial of methyl-GAG: a Southwest Oncology Group pilot study. Cancer Treat. Rep. 1979; 63: 1933–1937
   PubMedGoogle Scholar
• Hoffmann H., Gutshe W., Amlacher R., et al. Mitoguazone (methylgloxal bis(gyanylhydrazone)): its status and prospects. Arch. Geschwulstforsch 1989; 59: 135–148
   PubMedGoogle Scholar
• Weick J.K., Crowley J., Natale R.B., et al. A randomized trial of five cisplatinum-containing treatments in patients with metastatic non-small cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 1991; 9: 1157–1162
   PubMed Web of Science ®Google Scholar
• Hagemeister F.B., Tannir N., McLaughlin P., et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkins disease. J. Clin. Oncol. 1987; 5: 556–561
   PubMed Web of Science ®Google Scholar
• Levine A.M., Tulpule A., Tessman D., et al. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter trial. J. Clin. Oncol. 1997; 15: 1094–1103
   PubMed Web of Science ®Google Scholar
• Mikiciuk-Olasik E., Glowka M.L., Krezel I., et al. New mitoguazone analogues with anticancer activity. Pharm. Pharmacol. Commun. 1999; 5: 485–490
   Google Scholar
• Davidson K., Petit T., Izbicka E., et al. Mitoguazone induces apoptosis via a p53-independent mechanism. Anti-Cancer Drugs 1998; 9: 635–640
   PubMed Web of Science ®Google Scholar
• Kaneko H., Hibasami H., Satoh N., et al. Involvement of apoptosis and cyclin D1 gene repression in growth inhibition of T-47D human breast cancer cells by methylglyoxal bis(cyclopentylamidinohydrazone). Int. J. Mol. Med. 1998; 1: 931–936
   PubMed Web of Science ®Google Scholar
• Kaneko H., Hibasami H., Mori K., et al. Apoptosis induction in human breast cancer MRK-nu-1 cells by a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP). Anticancer Res. 1998; 18: 891–896
   PubMed Web of Science ®Google Scholar
• Investigational Brochure RMI 71, 782 (alpha-difluoromethylornithine). Merrell Dow Pharmaceuticals, 1981.
   Google Scholar
• Lund B., Hanson O.P., Theilade K., et al. Phase II study of gemcitabine (2′2′-difluorodeoxycytidine) in previously treated oovarian cancer patients. J. Natl Cancer Inst. 1994; 86: 1530–1533
   PubMed Web of Science ®Google Scholar
• Cormier Y., Eisenhauer E., Muldal A., et al. Gemcitabine is an active agent in previously untreated extensive small cell lung cancer (SCLC): a study of the National Cancer Institute of Canada Clinical Trial Group. Ann. Oncol. 1994; 5: 283–285
   PubMed Web of Science ®Google Scholar
• Anderson H., Lund B., Bach F., et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 1994; 12: 1821–1826
   PubMed Web of Science ®Google Scholar
• Gatzemeier U., Shepherd F.A., Le Chevalier T., et al. Activity of gemcitabine in patients with non-small-cell lung cancer: a multicentre, extended phase II study. Eur. J. Cancer 1996; 32A: 243–248
   PubMed Web of Science ®Google Scholar
• Casper E.S., Green M.R., Kelsen D.P., et al. Phase II trial of gemciabine (2′2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investig. New Drugs 1994; 12: 29–34
   PubMed Web of Science ®Google Scholar
• Carmichael J., Fink U., Russel R.C.G., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 1996; 73: 101–105
   PubMed Web of Science ®Google Scholar
• Carmichael J., Possinger K., Phillip P., et al. Advanced breast cancer: a phase II trial with gemcitabine. J. Clin. Oncol. 1995; 13: 2731–2736
   PubMed Web of Science ®Google Scholar
• Carmichael J., Walling J. Phase II activity of gemcitabine in advanced breast cancer. Semin. Oncol. 1996; 23(Suppl. 10)77–81
   PubMedGoogle Scholar
• Carmichael J. The role of femcitabine I the treatment of other tumours. Br. J. Cancer 1998; 78((Suppl. 3))21–25
   PubMedGoogle Scholar
• Locker G.J., Gnant M.F.X., Jakesz R., et al. Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. Anti-Cancer Drugs 2001; 12: 209–212
   PubMed Web of Science ®Google Scholar
• Zielinski C.C., Brodowicz T., Herscovici V., et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 2000; 9: 338–342
   PubMed Web of Science ®Google Scholar
• Carmichael J. The role of gemcitabine in the treatment of other tumours. Br. J. Cancer 1998; 78((Suppl. 3))21–25
   PubMedGoogle Scholar
• Vermorken J.B., Guastalla J.P., Hatty S.R., et al. Phase I study of gemcitabine using a once every 2 weeks schedule. Br. J. Cancer 1997; 76: 1489–1493
   PubMed Web of Science ®Google Scholar
• Von Hoff D.D. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. Investig. New Drugs 1996; 14: 265–270
   PubMed Web of Science ®Google Scholar
• Akrivakis K., Schmid P., Flath B., et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anti-cancer Drugs 1999; 10: 525–531
   PubMed Web of Science ®Google Scholar
• Schmid P., Akrivakis K., Flath B., et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-cancer Drugs 1999; 10: 625–631
   PubMed Web of Science ®Google Scholar
• Possinger K., Kaufmann M., Coleman R., et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-cancer Drugs 1999; 10: 155–162
   PubMed Web of Science ®Google Scholar
• Luftner D., Flath B., Akrivakis C., et al. Gemcitabine for palliative treatment in metastatic breast cancer. J. Cancer Res. Clin. Oncol. 1998; 124: 527–531
   PubMed Web of Science ®Google Scholar
• Plunkett W., Huang P., Xu Y.Z., et al. Gemcitabine: metabolism, mechanism of action and self-potentiation. Semin. Oncol. 1995; 22((Suppl. 11))3–10
   PubMedGoogle Scholar
• Smorenburg C.H., Bontenbal M., Seynaeve C., et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res. Treat. 2001; 66: 83–87
   PubMed Web of Science ®Google Scholar
• Rivera E., Bast R.C., Jr., Booser D., et al. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J. Clin. Oncol. 2001; 19: 1716–1722
   PubMed Web of Science ®Google Scholar
• Patnaik A., Drengler R.L., Eckhardt S.G., et al. Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. J. Clin. Oncol. 2000; 18: 3974–3985
   PubMed Web of Science ®Google Scholar
• Safa A.R., Bahadori H.R., Green M.R., et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 1999; 19: 5423–5428
   PubMed Web of Science ®Google Scholar
• Theodossiou C., Cook J.A., Fisher J., et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int. J. Oncol. 1998; 12: 825–832
   PubMed Web of Science ®Google Scholar
• de Boer R. Gemcitabine and vinorelbine in advanced breast cancer. Breast Cancer Res. 2000; 2: 368
   Google Scholar
• Bahadori H.R., Rocha L.C.M.S., Green M.R., et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 1999; 19: 5423–5428
   PubMed Web of Science ®Google Scholar
• Nicolaides C., Dimopoulos M.A., Samantas E., et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 2000; 11: 873–875
   PubMed Web of Science ®Google Scholar
• Valenza R., Leonardi V., Gebbia V., et al. Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann. Oncol. 2000; 11: 495–496
   PubMed Web of Science ®Google Scholar
• Fountzilas G., Nicolaides C., Bafaloukos D., et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Investig. 2000; 18: 503–509
   PubMed Web of Science ®Google Scholar
• Perez-Manga G., Lluch A., Alba E., et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J. Clin. Oncol. 2000; 18: 2545–2552
   PubMed Web of Science ®Google Scholar
• Frasci G., Comella P., D'Aiuto G., et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann. Oncol. 2000; 11: 367–371
   PubMed Web of Science ®Google Scholar
• Nagourney R.A., Link J.S., Blitzer J.B., et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J. Clin. Oncol. 2000; 18: 2245–2249
   PubMed Web of Science ®Google Scholar
• Mavroudis D., Malamos N., Alexopoulos A., et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann. Oncol. 1999; 10: 211–215
   PubMed Web of Science ®Google Scholar
• Luftner D., Flath B., Akrivakis C., et al. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Investig. New Drugs 1998; 16: 141–146
   PubMed Web of Science ®Google Scholar
• Zoli W., Ricotti L., Barzanti F., et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int. J. Cancer 1999; 80: 413–416
   PubMed Web of Science ®Google Scholar
• Safa A.R., Bahadori H.R., Green M.R., et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 1999; 19: 5423–5428
   PubMed Web of Science ®Google Scholar
• Budman D.R., Calabro A., Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anti-Cancer Drugs 1998; 9: 697–702
   PubMed Web of Science ®Google Scholar
• Kano Y., Akutsu M., Tsunoda S., et al. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines. Oncol. Res. 1998; 10: 347–354
   PubMed Web of Science ®Google Scholar
• Nordquist R.E., Ishmael D.R., Lovig C.A., et al. Tissue culture and morphology of human breast tumor cell line BOT-2. Cancer Res. 1975; 35: 3100–3105
   PubMed Web of Science ®Google Scholar
• Kim U. Metastasizing mammary carcinomas in rats: induction and study of their immunogenicity. Science 1970; 167: 72–74
   PubMed Web of Science ®Google Scholar
• Chatterjee S.K., Kim U. Fucosyltransferase activity in metastasizing and nonmetastasizing rat mammary carcinomas. J. Natl Cancer Inst. 1978; 61: 151–162
   PubMed Web of Science ®Google Scholar
• Chatterjee S.K., Kim U. Biochemical properties of cyclic nucleotide phosphodiesterase in metastasizing and nonmetastasizing rat mammary carcinomas. J. Natl Cancer Inst. 1976; 56: 105–110
   PubMed Web of Science ®Google Scholar
• Von Hoff D.D. MGBG: teaching an old drug new tricks. Ann. Oncol. 1994; 5: 487–493
   PubMed Web of Science ®Google Scholar
• Pleshkewych A., Kramer D.L., Kelly E., et al. Independence of drug action on mitochondria and polyamines in L1210 leukemia cells treated with methylgloxal bis(guanylhydrazone). Cancer Res. 1980; 40: 4533–4540
   PubMed Web of Science ®Google Scholar
• Huang P., Chubb S., Hertel L.W., et al. Mechanism of action of 2′2′-difluorodeoxycytidine triphosphate on DNA synthesis. Proc. AACR 1990; 31: 26
   Google Scholar
• Heinemann V., Xu Y.Z., Chubb S., et al. Cellular elimination of 2′2′-difluorodeoxycytidine 5′ triphosphate: a mechanism of self potentiation. Cancer Res. 1992; 5: 533–539
   Google Scholar
• Abbruzzese J.L., Grunewald R., Weeks E.A., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 1991; 9: 491–498
   PubMed Web of Science ®Google Scholar
• Porter C.W., Janne J. Modulation of antineoplastic drug action by inhibitors of polyamine biosynthesis. Inhibition of Polyamine Metabolism, P.P. McCann, A.E. Pegg, A. Sjoerdsman. Orlando Academic Press. 1987; 213–248
   Google Scholar